Company Overview
BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on developing and selling clinical-stage biopharmaceutical therapies focused on oncology and immunology. The company operates through two segments: the Plinabulin pipeline and the TPD platform. The company's lead asset is Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia (CIN). It also develops Plinabulin in combination with Plinabulin+docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy and radiation; nivolumab, a PD-1 antibody that has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer (ES-SCLC); in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small-molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.
Why Investors Should Care
Generates positive free cash flow, funding growth and shareholder returns internally.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -68.99% |
| 6 Months: | -58.09% |
| 3 Months: | -63.52% |
| 1 Month: | -28.71% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)31.01 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Generates positive free cash flow.
CONS
- Trading 73.6% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | BYSI BeyondSpring Inc. PHARMA | 0.62 | -3.44 | $25.49M | 0.00% | -72.39% | 3.13% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -2.06M | -2.64M | -2.36M | -2.61M | -1.95M | -1.79M | -2.23M |
| Net Income | -3.23M | -4.03M | -2.13M | 4.48M | -1.81M | -1.54M | -2.16M |
| Diluted EPS | - | -0.04 | - | - | -0.10 | - | - |
| R&D Expense | 721.00K | 829.00K | 622.00K | 874.00K | 1.00M | 1.04M | 1.08M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Revenue | 0 | 0 | 0 |
| Operating Income | -15.08M | -8.75M | -8.95M |
| Net Income | -21.03M | -11.12M | -1.01M |
| R&D Expense | 7.27M | 2.64M | 4.39M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 46.22M | 24.81M | 34.31M | 25.93M |
| Current Assets | - | 38.52M | 18.42M | 28.58M | 20.88M |
| Cash & Equivalents | - | 34.40M | 5.40M | 2.92M | 7.79M |
| Inventory | - | - | - | - | - |
| Receivables | - | - | - | - | - |
| Total Liabilities | - | 49.23M | 48.27M | 48.60M | 49.92M |
| Current Liabilities | - | 7.35M | 7.96M | 11.01M | 13.58M |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | 4.96M | 847.00K | 589.00K | 320.00K |
| Total Equity | - | -5.98M | -26.80M | -32.90M | -32.16M |
| Shares Outstanding | - | 39.00M | 39.03M | 40.32M | 41.12M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Operating Cash Flow | -16.47M | -16.44M | -19.77M |
| Investing Cash Flow | -100.00K | -12.01M | 10.79M |
| Financing Cash Flow | 4.00K | 26.79M | 4.97M |
| Capital Expenditure | -100.00K | -224.00K | -50.00K |
| Free Cash Flow | -16.57M | -16.67M | -19.82M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Gross Margin % | - | - | - |
| Operating Margin % | - | - | - |
| Net Margin % | - | - | - |
| ROE % | 78.4% | 33.8% | 3.1% |
| ROCE % | -89.5% | -37.6% | -72.4% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Decheng Capital LLC | 9.24% | 3.80M | $2.85M |
| 2 | Blackrock Inc. | 1.64% | 672.91K | $504.55K |
| 3 | Vanguard Capital Management LLC | 1.52% | 626.46K | $469.72K |
| 4 | Geode Capital Management, LLC | 0.89% | 367.74K | $275.73K |
| 5 | State Street Corporation | 0.56% | 231.12K | $173.29K |
| 6 | Vanguard Fiduciary Trust Co | 0.44% | 181.20K | $135.86K |
| 7 | UBS Group AG | 0.15% | 63.03K | $47.26K |
| 8 | Northern Trust Corporation | 0.15% | 62.02K | $46.51K |
| 9 | Meridian Wealth Management, LLC | 0.04% | 15.00K | $11.25K |
| 10 | Farther Finance Advisors, Llc | 0.03% | 12.77K | $9.58K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for BYSI
BeyondSpring Inc. SEC Filing (Sep 3, 2026) - Stock Titan
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxPSjNvUFRCMGlwWFdyR2xlSGlZWlBRc3IzMDhZUHlZOHViNlF2RHN0VHNvMUNhdkZNTlBYX0c1Zy1ZWnFlZWI3TUM2Vk00d3FjSWhLSjRhMVBIMXM3NVdJRGk3aThNWnBTWmpYTGVZdVAwS3Y5LUZLN2RCUDFSV2JDTFR3a0VqZjluV2JHVV…
BeyondSpring Posts $5.7 Million Second-Quarter Net Loss - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxPRWNrQWxaSFdKMkl1M1ozZVgtSWJIdkVfeHFGLUgtTUJoemV5ZHhWZDdFRElfTzVGRTZoVTdZX055SEVwODZ4YVpxMjUtSTJHSUxnOHc3X2tLeXVEaTUzS1VzVDRDdFZrNGxvd202TkcwMHJRSFdPRlZ1ZGk2dEJNbnZEY3J0QThyN0s1c0…
BYSI - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE1TNkpxR2drZG9BUEVUUnBVN3YwU2pmRGRIVjFrR0lGVThjaS15OXhYYWt5MjN3ZkRFQUNGa3d5SU9ESlVTcEE?oc=5" target="_blank">BYSI</a> <font color="#6f6f6f">Finviz</font>…
BeyondSpring (BYSI) plans Oct. 13 vote on 2026 auditor - Stock Titan
<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxQX1FTOFctUmJkN2dwVEUyNmZWWHdKclhHZlRYUkhCVFdjWVctR2N3WFdRa0VNMHZaMVkwWDh1cE5PYnNpY01kMnVnRS1xYTNBcGxvYkJwa2owZUU4V0tLaG9JRFBOZUFtY0FEaUhXdGxkcDFHM2JmcjNiXzlzZWtlX2liNk5CRnljOHNHZ3…
BeyondSpring Reports First-Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewswire
<a href="https://news.google.com/rss/articles/CBMi8AFBVV95cUxQbFVhWnJZckpZNTlnU0FmQ1RSalBwVXRvTmtvdWJOQVdZSFhQQnNsVkMyelJTNFo0alRMUVFlekJaYU1jNGNxWkpkWjBVajVuTnJUeHJvMmcyM2VJVVlCTFB5QzlXMmpQWGZUajlTQUItQjZLUXVPc2JCYnphb0NDczBabXc4LWtaOUpBSl…
Here's Why We're A Bit Worried About BeyondSpring's (NASDAQ:BYSI) Cash Burn Situation - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxPR1FCZVV6TTNBVlZUM1pCV1k1bG5LbGxCNEVpMTR3Y0VJQjZHY1gtZjgzTUlrZXRORm11VlM1Q0hWOGE2TGV0UWpsUEk1STczZUdTVVNTaGhDV0dhNEZmSGdpa1lCS1RhT0ZrR3ktN0JXeEFFYjBibWVyVWk5dVdPV2lMX2U5SG5RTmtCVU…
BYSI — Frequently Asked Questions
What is the current share price of BeyondSpring Inc. (BYSI)?
As of 2026-09-19 21:16 PDT, BeyondSpring Inc. (BYSI) trades at $0.62 on NasdaqCM. Its 52-week range is $0.60 to $2.35.
What is the market capitalisation of BYSI?
BeyondSpring Inc. (BYSI) has a market capitalisation of $25.49M on NasdaqCM.
What is the P/E ratio of BYSI?
BYSI trades at a trailing price-to-earnings (P/E) ratio of -3.44. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is -0.73.
What is the return on equity (ROE) of BYSI?
BYSI has a return on equity (ROE) of 3.13%. Its return on capital employed (ROCE) is -72.39%.
Is BYSI a good stock to buy?
This page provides a data-driven analysis of BeyondSpring Inc. (BYSI), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.